Who is sponsoring NCT04851314?

NCT04851314 is sponsored by University of California, Irvine.

What drugs are being tested in NCT04851314?

Interventions in NCT04851314: ICU certified ventilator, Non-ICU certified ventilator.

What condition does NCT04851314 study?

NCT04851314 studies Anesthetic Gas Consumption and Cost-Effectiveness.

Is NCT04851314 still recruiting?

NCT04851314 is currently completed. Last updated 10 August 2021.

Are results published for NCT04851314?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-08-10 · How we verify

NCT04851314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Different Ventilator and Vaporizer Technologies to Study Economic and Environmental Implications

Completed NA Results posted Last updated 10 August 2021

What this trial tests

NA trial testing ICU certified ventilator in Anesthetic Gas Consumption and Cost-Effectiveness in 110 participants. Completed in 8 November 2019.

Timeline

14 February 2018

Primary endpoint
8 November 2019

8 November 2019

Quick facts

Lead sponsor	University of California, Irvine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	110
Start date	14 February 2018
Primary completion	8 November 2019
Estimated completion	8 November 2019
Sites	1 location across United States

Drugs / interventions tested

ICU certified ventilator
Non-ICU certified ventilator

Conditions studied

Anesthetic Gas Consumption and Cost-Effectiveness — all drugs for Anesthetic Gas Consumption and Cost-Effectiveness →

Sponsor

University of California, Irvine

Who can join

Adults 18 to 65, any sex, with Anesthetic Gas Consumption and Cost-Effectiveness. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Primary Study Variable: Amount of Gas Vaporized Anesthetic Per Minute Anesthesia Primary · Intraoperative (minimum of 2 hours of anesthesia)

The purpose of this study is to test whether or not the use of a low volume ventilator in an anesthesia machine reduces anesthetic costs significantly as compared to other high volume machines. The study will compare the FLOW-i anesthesia machine to a GE anesthesia machine during routine elective general surgery in patients with ASA ratings of 1-2 under general anesthesia receiving standard care.

Group	Value	95% CI
Maquet Flow-i C20	95.48	± 49.29
GE Aisys CS2	119.3	± 62.22

Time to Reach Aldrete > 8 Secondary · Up to 24 hours

Time it took for patient to be safely discharged from the post-anesthesia care unit (PACU). The Aldrete Score evaluates recovery after anesthesia and patient readiness to be discharged from PACU. The patient is assessed for consciousness, mobility, breathing, circulation, and color. The evaluation occurs immediately after surgery and then every (1) hour before the patient is deemed ready for discharge.

Group	Value	95% CI
Maquet Flow-i C20	98.13	± 51.83
GE Aisys CS2	89.18	± 52.09

Time to Extubation From Weaning Secondary · Intraoperative (minimum of 2 hours of anesthesia)

Time it took to remove patient from mechanical ventilation

Group	Value	95% CI
Maquet Flow-i C20	10.37	± 6.321
GE Aisys CS2	10.78	± 6.413

Sponsor's own description

The purpose of this study is to test whether or not the use of a low volume ventilator in an anesthesia machine reduces anesthetic costs significantly as compared to other high volume machines. The study will compare the a low-flow anesthesia machine to a traditional anesthesia machine during routine elective general surgery in patients with ASA ratings of 1-2 under general anesthesia receiving standard care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04851314 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04851314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing